Drugs / GSK576389A
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 25 trials | ||||||
| Phase 2 | NCT00633074 | Mar → Apr 2008 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00538473 | Oct → Dec 2007 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00538213 | Oct → Nov 2007 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00540592 | Oct 2007 → Jun 2008 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00532298 | Sep → Nov 2007 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00529516 | Oct → Dec 2007 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK576389A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00540592 ↗ |
| Known as | FluAS25 | “Thiomersal-free FluAS25 adjuvanted vaccine (GSK576389A)” NCT00633074 ↗ |
| Modality | Vaccine | “GSK Biologicals' influenza vaccine GSK576389A” NCT00529516 ↗ |
| Route | Intramuscular | “Single dose, Intramuscular injection” NCT00529516 ↗ |